Antibody affinity maturation and cross-variant activity following SARS-CoV-2 mRNA vaccination: Impact of prior exposure and sex
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Antibody affinity maturation and cross-variant activity following SARS-CoV-2 mRNA vaccination: Impact of prior exposure and sex
Authors
Keywords
SARS-CoV-2, COVID-19, Vaccine, Virus neutralization, Affinity maturation, Sex differences
Journal
EBioMedicine
Volume 74, Issue -, Pages 103748
Publisher
Elsevier BV
Online
2021-12-10
DOI
10.1016/j.ebiom.2021.103748
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- New mutations raise specter of ‘immune escape’
- (2021) Kai Kupferschmidt SCIENCE
- Viral evolution may herald new pandemic phase
- (2021) Kai Kupferschmidt SCIENCE
- Fast-spreading U.K. virus variant raises alarms
- (2021) Kai Kupferschmidt SCIENCE
- Maturation and persistence of the anti-SARS-CoV-2 memory B cell response
- (2021) Aurélien Sokal et al. CELL
- SARS-CoV-2 Viral Variants—Tackling a Moving Target
- (2021) John R. Mascola et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- SARS-CoV-2 variants and ending the COVID-19 pandemic
- (2021) Arnaud Fontanet et al. LANCET
- Antibody Resistance of SARS-CoV-2 Variants B.1.351 and B.1.1.7
- (2021) Pengfei Wang et al. NATURE
- SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma
- (2021) Constantinos Kurt Wibmer et al. NATURE MEDICINE
- Serum Neutralizing Activity Elicited by mRNA-1273 Vaccine — Preliminary Report
- (2021) Kai Wu et al. NEW ENGLAND JOURNAL OF MEDICINE
- Antibody affinity maturation and plasma IgA associate with clinical outcome in hospitalized COVID-19 patients
- (2021) Juanjie Tang et al. Nature Communications
- Longitudinal antibody repertoire in “mild” versus “severe” COVID-19 patients reveals immune markers associated with disease severity and resolution
- (2021) Supriya Ravichandran et al. Science Advances
- SARS-CoV-2 spike variants exhibit differential infectivity and neutralization resistance to convalescent or post-vaccination sera
- (2021) Alona Kuzmina et al. Cell Host & Microbe
- Increased resistance of SARS-CoV-2 variant P.1 to antibody neutralization
- (2021) Pengfei Wang et al. Cell Host & Microbe
- SARS-CoV-2 variants and convalescent plasma: reality, fallacies, and opportunities
- (2021) Arturo Casadevall et al. JOURNAL OF CLINICAL INVESTIGATION
- Neutralizing antibody vaccine for pandemic and pre-emergent coronaviruses
- (2021) Kevin O. Saunders et al. NATURE
- Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection
- (2021) David S. Khoury et al. NATURE MEDICINE
- Antibody responses to the BNT162b2 mRNA vaccine in individuals previously infected with SARS-CoV-2
- (2021) Joseph E. Ebinger et al. NATURE MEDICINE
- BNT162b2-Elicited Neutralization against New SARS-CoV-2 Spike Variants
- (2021) Yang Liu et al. NEW ENGLAND JOURNAL OF MEDICINE
- mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection
- (2021) Leonidas Stamatatos et al. SCIENCE
- Prior SARS-CoV-2 infection rescues B and T cell responses to variants after first vaccine dose
- (2021) Catherine J. Reynolds et al. SCIENCE
- The emerging plasticity of SARS-CoV-2
- (2021) Kevin D. McCormick et al. SCIENCE
- Distinct antibody and memory B cell responses in SARS-CoV-2 naïve and recovered individuals following mRNA vaccination
- (2021) Rishi R. Goel et al. Science Immunology
- Quantitative SARS-CoV-2 anti-spike responses to Pfizer–BioNTech and Oxford–AstraZeneca vaccines by previous infection status
- (2021) David W. Eyre et al. CLINICAL MICROBIOLOGY AND INFECTION
- Marked Increase in Avidity of SARS-CoV-2 Antibodies 7–8 Months After Infection Is Not Diminished in Old Age
- (2021) Daniel Pichler et al. JOURNAL OF INFECTIOUS DISEASES
- Neutralising antibody activity against SARS-CoV-2 VOCs B.1.617.2 and B.1.351 by BNT162b2 vaccination
- (2021) Emma C Wall et al. LANCET
- BNT162b2-elicited neutralization of B.1.617 and other SARS-CoV-2 variants
- (2021) Jianying Liu et al. NATURE
- Antibodies elicited by mRNA-1273 vaccination bind more broadly to the receptor binding domain than do those from SARS-CoV-2 infection
- (2021) Allison J. Greaney et al. Science Translational Medicine
- Mapping mutations to the SARS-CoV-2 RBD that escape binding by different classes of antibodies
- (2021) Allison J. Greaney et al. Nature Communications
- Epitope diversity of SARS-CoV-2 hyperimmune intravenous human immunoglobulins and neutralization of variants of concern
- (2021) Juanjie Tang et al. iScience
- mRNA vaccines induce durable immune memory to SARS-CoV-2 and variants of concern
- (2021) Rishi R. Goel et al. SCIENCE
- Longitudinal Human Antibody Repertoire against Complete Viral Proteome from Ebola Virus Survivor Reveals Protective Sites for Vaccine Design
- (2020) Surender Khurana et al. Cell Host & Microbe
- Antibody signature induced by SARS-CoV-2 spike protein immunogens in rabbits
- (2020) Supriya Ravichandran et al. Science Translational Medicine
- Differential human antibody repertoires following Zika infection and the implications for serodiagnostics and disease outcome
- (2019) Supriya Ravichandran et al. Nature Communications
- Anti-influenza hyperimmune intravenous immunoglobulin for adults with influenza A or B infection (FLU-IVIG): a double-blind, randomised, placebo-controlled trial
- (2019) Richard T Davey et al. Lancet Respiratory Medicine
- H5 N-terminal β sheet promotes oligomerization of H7-HA1 that induces better antibody affinity maturation and enhanced protection against H7N7 and H7N9 viruses compared to inactivated influenza vaccine
- (2014) Surender Khurana et al. VACCINE
- Oligomeric Recombinant H5 HA1 Vaccine Produced in Bacteria Protects Ferrets from Homologous and Heterologous Wild-Type H5N1 Influenza Challenge and Controls Viral Loads Better than Subunit H5N1 Vaccine by Eliciting High-Affinity Antibodies
- (2012) S. Verma et al. JOURNAL OF VIROLOGY
- AID Activity in B Cells Strongly Correlates with Polyclonal Antibody Affinity Maturation in-vivo Following Pandemic 2009-H1N1 Vaccination in Humans
- (2012) Surender Khurana et al. PLoS Pathogens
- MF59 Adjuvant Enhances Diversity and Affinity of Antibody-Mediated Immune Response to Pandemic Influenza Vaccines
- (2011) S. Khurana et al. Science Translational Medicine
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now